# A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

> **NCT00721344** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 48 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Technosphere Inhalation Powder (FDKP)
- **DRUG:** Moxifloxacin
- **DRUG:** Technosphere Inhalation Powder (FDKP)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00721344
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721344, "A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00721344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*